New Clinical Data Access Policy, Portfolio Expansions, Positive Top Line Results and Stock Price Movements - Research Report on

   New Clinical Data Access Policy, Portfolio Expansions, Positive Top Line
  Results and Stock Price Movements - Research Report on Pfizer, Amgen, Puma
               Biotechnology, Abbott Laboratories, and Agilent

PR Newswire

NEW YORK, December 10, 2013

NEW YORK, December 10, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Pfizer
Inc. (NYSE: PFE), Amgen, Inc. (NASDAQ: AMGN), Puma Biotechnology Inc. (NYSE:
PBYI), Abbott Laboratories (NYSE: ABT) and Agilent Technologies Inc. (NYSE:
A). Today's readers may access these reports free of charge - including full
price targets, industry analysis and analyst ratings - via the links below.

Pfizer Inc. Research Report

On December 4, 2013, Pfizer Inc. (Pfizer) announced an update of its clinical
data access policy that will simplify and broaden access to information
gathered in Pfizer-sponsored clinical trials. According to Pfizer, the updated
policy meets or exceeds the "Principles of Responsible Data Sharing" issued by
the Pharmaceutical Research and Manufacturers of America (PhRMA) and the
European Federation of Pharmaceutical Industries and Associations (EFPIA) in
July 2013. Pfizer said that the updated policy builds upon and expands the
Company's established methods of clinical trial information sharing, including
Pfizer's long track record of submitting for publication results from all
interventional clinical trials in patients and its pioneering efforts to
provide clinical trial results and data to study participants. In addition,
the Company stated that its expanded clinical data access policy also
reinforces its current practice of submitting for publication manuscripts for
all interventional clinical trials in patients, regardless of outcomes, within
18 months of study completion, and Pfizer's commitment to register and post
summary results for interventional human clinical trials to clinicaltrials.gov
in the United States and to registries outside the United States, as required.
The Full Research Report on Pfizer Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/d702_PFE

--

Amgen, Inc. Research Report

On December 5, 2013 Amgen, Inc.'s (Amgen) stock rose 0.25%, ending the day at
$113.35. Over the previous three trading sessions, shares of Amgen declined
0.98% compared to the Nasdaq Composite which declined 0.30% during the same
period. The Full Research Report on Amgen, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/e96b_AMGN

--

Puma Biotechnology Inc. Research Report

On December 4, 2013, Puma Biotechnology, Inc. (Puma Bio) announced top line
results from the Phase II clinical trial of Puma's investigational drug
(PB272) neratinib for the neoadjuvant treatment of breast cancer (I-SPY 2
TRIAL). According to the Company, the I-SPY 2 TRIAL is a randomized Phase II
clinical trial for women with newly diagnosed Stage 2 or higher (tumor size at
least 2.5 cm) breast cancer that addresses whether adding investigational
drugs to standard chemotherapy in the neoadjuvant setting is better than
standard chemotherapy. Puma Bio stated that the goal of the trial is to match
investigational regimens with patient subsets on the basis of molecular
characteristics (biomarker signatures) that benefit from the regimen. The
Company also revealed that the neratinib-containing regimen graduated from the
I-SPY 2 TRIAL based on having a high probability of success in Phase III with
a signature of HER2-positive/HR-negative. It further added that in this group,
treatment with the neratinib-containing regimen resulted in a higher pCR rate
compared to the control arm (standard neoadjuvant chemotherapy: paclitaxel in
combination with Herceptin (trastuzumab), followed by doxorubicin and
cyclophosphamide). The Full Research Report on Puma Biotechnology Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/4d27_PBYI

--

Abbott Laboratories Research Report

On December 5, 2013, Abbott Laboratories' (Abbott) stock declined 1.18%,
ending the day at $36.92. Over the previous three trading sessions, shares of
Abbott declined 3.20% compared to the S&P 500 which declined 0.88% during the
same period. The Full Research Report on Abbott Laboratories - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/05c1_ABT

--

Agilent Technologies Inc. Research Report

On December 4, 2013, Agilent Technologies Inc. (Agilent) expanded its range of
signal generators with two new models: N5183B MXG and N5173B EXG. According to
the Company, these new microwave analog signal generators provide unmatched
performance in phase noise, output power and frequency-switching speed.
Agilent stated that the N5183B MXG analog is an alternative to the high
performance PSG, and offers accuracy, efficiency, and near-PSG performance in
only two rack units. In addition, Agilent stated that the N5173B EXG analog is
a cost-effective option when system creators need to balance budget and
performance, and offers the best combination of output power (+20 dBm at 20
GHz) and low harmonics (<-55 dBc), making it well-suited to the
characterization of broadband microwave components such as filters and
amplifiers. The Full Research Report on Agilent Technologies Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/075e_A

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)